Pear Therapeutics, Inc. Warrant
PEARW
PEARW was delisted on the 18th of April, 2023.
0 hedge funds and large institutions have $0 invested in Pear Therapeutics, Inc. Warrant in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $277 → $0 (-$277)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AR
Advisory Research
Chicago,
Illinois
|
-$208 |
| 2 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
-$69 |
PEARW Hedge Fund Activity: Q3 2023 in Review
0 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Warrant (PEARW) for Q3 2023, worth a combined $0 — down 100% from $277 a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PEARW and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Advisory Research, exiting entirely with an estimated $208 sold.
- 0 institutional investors held Pear Therapeutics, Inc. Warrant (PEARW) as of Q3 2023, down from 2 in Q2 2023.
- Funds reported $0 of Pear Therapeutics, Inc. Warrant stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Pear Therapeutics, Inc. Warrant positions in Q3 2023 and 2 closed out, a net change of -2 holders.
- The largest Pear Therapeutics, Inc. Warrant seller in Q3 2023 was Advisory Research, an estimated $208 sold.
Based on aggregated 13F filings for Q3 2023.